Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 290, Issue 1, 2006, Pages

  Ishimura, Norihisa ^a   Isomoto, Hajime ^a   Bronk, Steven F ^a   Gores, Gregory J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cholangiocyte; Malignant phenotype; Nuclear factor B; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; APOPTOSIS REGULATORY PROTEIN; MEMBRANE PROTEIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER THERAPY; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; PHENOTYPE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION; BILE DUCT TUMOR; CELL MOTION; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHOLANGIOCARCINOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 33644801980     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00242.2005     Document Type: Article

References (51)

1. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, and Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
2. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107: 3-6, 2001.
3. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, and Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 23: 3175-3185, 2004.
4. Berthiaume EP and Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 24: 127-137, 2004.
5. Burak K, Angulo P, Pasha TM, Egan K, Petz J, and Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 99: 523-526, 2004.
6. Di Pietro R and Zauli G. Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201: 331-340, 2004.
7. Dienes HP, Lohse AW, Gerken G, Schirmacher P, Gallati H, Lohr HF, and Meyer zum Buschenfelde KH. Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch 431: 119-124, 1997.
8. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, and Jeremias I. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 22: 3842-3852, 2003.
9. Fiebiger WC, Scheithauer W, Traub T, Kurtaran A, Gedlicka C, Kornek GV, Virgolini I, and Raderer M. Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression. Scand J Gastroenterol 37: 222-225, 2002.
10. Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, Nguyen T, and Hersey P. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166: 5337-5345, 2001.
11. Ghosh S, May MJ, and Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260, 1998.
12. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 37: 961-969, 2003.
13. Han C and Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invation through EP1 receptor-mediated activation of epidermal growth factor receptor and Akt. J Biol Chem 280: 24053-24063, 2005.
14. Harnois DM, Que FG, Celli A, LaRusso NF, and Gores GJ. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 26: 884-890, 1997.
15. Hejna M, Pruckmayer M, and Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34: 977-986, 1998.
16. Helbig G, Christopherson KW, 2nd Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, and Nakshatri H. NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278: 21631-21638, 2003.
17. Iimuro Y, Nishiura T, Hellerbrand C, Behrns KE, Schoonhoven R, Grisham JW, and Brenner DA. NFkappaB prevents apoptosis and liver dysfunction during liver regeneration. J Clin Invest 101: 802-811, 1998.
18. Inoue H, Shiraki K, Yamanaka T, Ohmori S, Sakai T, Deguchi M, Okano H, Murata K, Sugimoto K, and Nakano T. Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonic adenocarcinoma cells. Lab Invest 82: 1111-1119, 2002.
19. Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA, and Sartor RB. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor kappaB super-repressor in human intestinal epithelial cells. J Immunol 160: 410-418, 1998.
20. Karacay B, Sanlioglu S, Griffith TS, Sandler A, and Bonthius DJ. Inhibition of the NF-kappaB pathway enhances TRAIL-mediated apoptosis in neuroblastoma cells. Cancer Gene Ther 11: 681-690, 2004.
21. Kim YS, Schwabe RF, Qian T, Lemasters JJ, and Brenner DA. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 36: 1498-1508, 2002.
22. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W, and Meyer zum Buschenfelde KH. Biliary adenocarcinoma Characterisation of three new human tumor cell lines. J Hepatol 1: 579-596, 1985.
23. Kobayashi S, Werneburg N, Bronk S, Kaufmann S, and Gores GJ. Interleukin-6 contributes to Mcl-1 upregulation and TRAIL resistance via an Akt signaling pathway in cholangiocarcinoma cells. Gastroenterology 128: 2054-2065, 2005.
24. Kwo P, Patel T, Bronk SF, and Gores GJ. Nuclear serine protease activity contributes to bile acid-induced apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 268: G613-G621, 1995.
25. Lazaridis KN and Gores GJ. Cholangiocarcinoma. Gastroenterology 128: 1655-1667, 2005.
26. Legembre P, Schickel R, Barnhart BC, and Peter ME. Identification of SNF1/AMP kinase-related kinase as an NF-kappaB-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness. J Biol Chem 279: 46742-46747, 2004.
27. Murakami T, Yano H, Maruiwa M, Sugihara S, and Kojiro M. Establishment and characterization of a human combined hepatocholangiocarcinoma cell line and its heterologous transplantation in nude mice. Hepatology 7: 551-556, 1987.
28. Ozawa F, Friess H, Kleeff J, Xu ZW, Zimmermann A, Sheikh MS, and Buchler MW. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett 163: 71-81, 2001.
29. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, and Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113, 1997.
30. Pickens A, Pan G, McDonald JM, and Vickers SM. Fas expression prevents cholangiocarcinoma tumor growth. J Gastrointest Surg 3: 374-382, 1999.
31. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, and Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466, 2004.
32. Que FG, Phan VA, Phan VH, Celli A, Batts K, LaRusso NF, and Gores GJ. Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology 30: 1398-1404, 1999.
33. Roberts SK, Ludwig J, and Larusso NF. The pathobiology of biliary epithelia. Gastroenterology 112: 269-279, 1997.
34. Rust C, Karnitz LM, Paya CV, Moscat J, Simari RD, and Gores GJ. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 275: 20210-20216, 2000.
35. Secchiero P, Gonelli A, Carnevale E, Corallini F, Rizzardi C, Zacchigna S, Melato M, and Zauli G. Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 6: 364-373, 2004.
36. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, and Zauli G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107: 2250-2256, 2003.
37. Shaib Y and El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24: 115-125, 2004.
38. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15, 2005.
39. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, and de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9: 3397-3405, 2003.
40. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, and Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37: 87-95, 2003.
41. Tanaka S, Sugimachi K, Shirabe K, Shimada M, and Wands JR. Expression and antitumor effects of TRAIL in human cholangiocarcinoma. Hepatology 32: 523-527, 2000.
42. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, and Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 64: 3517-3524, 2004.
43. Tanimura Y, Kokuryo T, Tsunoda N, Yamazaki Y, Oda K, Nimura Y, Naing Mon N, Huang P, Nakanuma Y, Chen MF, Jan YY, Yeh TS, Chiu CT, Hsieh LL, and Hamaguchi M. Tumor necrosis factor alpha promotes invasiveness of cholangiocarcinoma cells via its receptor, TNFR2. Cancer Lett 219: 205-213, 2005.
44. Tjandra K, Sharkey KA, and Swain MG. Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis. Hepatology 31: 280-290, 2000.
45. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 47: 644-649, 2000.
46. Tolcher A, Mita M, Patnaik A, Rowinsky E, Corey A, Fleming M, Fox N, Weiner L, Meropol N, and Cohen R. A phase I and pharmacokinetic study of HGS-ETR1 (TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. J Clin Oncol 22: 3060, 2004.
47. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S, Roder C, Ungefroren H, Lampe E, Heinrich M, Walczak H, and Kalthoff H. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 20: 4258-4269, 2001.
48. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, and Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16: 5386-5397, 1997.
49. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, and Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
50. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, and Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
51. Yano H, Maruiwa M, Iemura A, Mizoguchi A, and Kojiro M. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC). Cancer 69: 1664-1673, 1992.